RusnanoMedInvest

RusnanoMedInvest is a venture capital firm specializing in innovative developments in the pharmaceutical and biotechnology sectors. The firm focuses on projects that involve the transfer of intellectual property rights and modern pharmaceutical production technology to Russia. Its mission is to create a Russian-domiciled center of world-class expertise in venture capital fundraising, deal origination, and execution in life sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting-edge technologies.

The firm's investment strategy encompasses a wide range of stages, including seed, early stage, Series A, Series B, growth, and late stage investments. Geographically, RusnanoMedInvest concentrates its efforts in Russia and the United States, aiming to bridge the gap between these markets by facilitating the transfer of advanced pharmaceutical technologies. The firm is particularly interested in projects that demonstrate significant potential for social and developmental impact within Russia.

RusnanoMedInvest has a history of active engagement in the pharmaceutical and biotechnology sectors, with notable investments such as the $21 million Series C financing in Marinus Pharmaceuticals in 2013. This investment was part of a syndicate that included Domain Associates, Canaan Partners, Sofinnova Ventures, and Foundation Medical Partners. The financing aimed to support the development of Ganaxolone, a neuroactive steroid for the treatment of neurological and psychiatric disorders. Additionally, in 2013, RusnanoMedInvest led a $6.7 million Series C funding round in Neothetics, a clinical-stage specialty pharmaceutical company developing therapeutics in aesthetic medicine and ophthalmology. These investments underscore the firm's commitment to advancing medical technologies and supporting innovative solutions in the healthcare sector.

In July 2025, RusnanoMedInvest, along with other entities, was reported to be seeking buyers for its major pharmaceutical asset, Novamedica, indicating a strategic shift in its investment focus. This move aligns with RusnanoMedInvest's ongoing efforts to realign its portfolio and concentrate on core activities, including energy logistics, nature management, and infrastructure. The decision reflects the firm's adaptive strategy in response to evolving market conditions and its commitment to promoting social and developmental objectives within Russia.